Trial · NCT03253913
Results by group27
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 27
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Serum Vascular Endothelial Growth Factor-D (VEGF-D) Levels After Treatment With a Combination of Resveratrol and Sirolimus as Compared to Baseline Serum VEGF-D Levels on Sirolimus Alone | Treatment Arm | Baseline VEGF-D level in patients on a stable dose of sirolimus alone | 617 | Inter-Quartile Range 489 to 677 | pg/ml |
| Serum Vascular Endothelial Growth Factor-D (VEGF-D) Levels After Treatment With a Combination of Resveratrol and Sirolimus as Compared to Baseline Serum VEGF-D Levels on Sirolimus Alone | Treatment Arm | Week 8 | 543 | Inter-Quartile Range 455 to 704 | pg/ml |
| Serum Vascular Endothelial Growth Factor-D (VEGF-D) Levels After Treatment With a Combination of Resveratrol and Sirolimus as Compared to Baseline Serum VEGF-D Levels on Sirolimus Alone | Treatment Arm | Week 16 | 581 | Inter-Quartile Range 485 to 724 | pg/ml |
| Serum Vascular Endothelial Growth Factor-D (VEGF-D) Levels After Treatment With a Combination of Resveratrol and Sirolimus as Compared to Baseline Serum VEGF-D Levels on Sirolimus Alone | Treatment Arm | Week 24 | 575 | Inter-Quartile Range 448 to 673 | pg/ml |
| Number of Treatment-Emergent Adverse Events | Treatment Arm | 250 mg daily | 42 | Adverse effects | |
| Number of Treatment-Emergent Adverse Events | Treatment Arm | 500mg daily | 25 | Adverse effects | |
| Number of Treatment-Emergent Adverse Events | Treatment Arm | 1000mg daily | 25 | Adverse effects | |
| Change in Forced Expiratory Volume in One-second (FEV1) After 24 Weeks of Combined Treatment With Resveratrol and Sirolimus | Treatment Arm | Baseline | 1.74 | Inter-Quartile Range 1.46 to 2.3 | Absolute FEV1 in liters |
| Change in Forced Expiratory Volume in One-second (FEV1) After 24 Weeks of Combined Treatment With Resveratrol and Sirolimus | Treatment Arm | Week 8 | 1.98 | Inter-Quartile Range 1.4 to 2.36 | Absolute FEV1 in liters |
| Change in Forced Expiratory Volume in One-second (FEV1) After 24 Weeks of Combined Treatment With Resveratrol and Sirolimus | Treatment Arm | Week 16 | 2.01 | Inter-Quartile Range 1.18 to 2.57 | Absolute FEV1 in liters |
| Change in Forced Expiratory Volume in One-second (FEV1) After 24 Weeks of Combined Treatment With Resveratrol and Sirolimus | Treatment Arm | Week 24 | 1.94 | Inter-Quartile Range 1.2 to 2.59 | Absolute FEV1 in liters |
| St. George's Respiratory Questionnaire (SGRQ) Quality of Life Assessment Scores After Treatment With Combined Resveratrol and Sirolimus | Treatment Arm | Baseline | 42 | Inter-Quartile Range 39 to 46 | score on a scale |
| St. George's Respiratory Questionnaire (SGRQ) Quality of Life Assessment Scores After Treatment With Combined Resveratrol and Sirolimus | Treatment Arm | Week 8 | 43.5 | Inter-Quartile Range 38 to 49 | score on a scale |
| St. George's Respiratory Questionnaire (SGRQ) Quality of Life Assessment Scores After Treatment With Combined Resveratrol and Sirolimus | Treatment Arm | Week 16 | 43 | Inter-Quartile Range 40 to 49 | score on a scale |
| St. George's Respiratory Questionnaire (SGRQ) Quality of Life Assessment Scores After Treatment With Combined Resveratrol and Sirolimus | Treatment Arm | Week 24 | 42 | Inter-Quartile Range 39 to 47 | score on a scale |
| Scores on A Tool to Assess Quality of Life in LAM (ATAQ-LAM) Quality of Life Assessment Scale After Treatment With 24 Weeks of Resveratrol and Sirolimus | Treatment Arm | Baseline | 72 | Inter-Quartile Range 54 to 88 | score on a scale |
| Scores on A Tool to Assess Quality of Life in LAM (ATAQ-LAM) Quality of Life Assessment Scale After Treatment With 24 Weeks of Resveratrol and Sirolimus | Treatment Arm | Week 8 | 70 | Inter-Quartile Range 49 to 101 | score on a scale |
| Scores on A Tool to Assess Quality of Life in LAM (ATAQ-LAM) Quality of Life Assessment Scale After Treatment With 24 Weeks of Resveratrol and Sirolimus | Treatment Arm | Week 16 | 60 | Inter-Quartile Range 44 to 82 | score on a scale |
| Scores on A Tool to Assess Quality of Life in LAM (ATAQ-LAM) Quality of Life Assessment Scale After Treatment With 24 Weeks of Resveratrol and Sirolimus | Treatment Arm | Week 24 | 57 | Inter-Quartile Range 47 to 87 | score on a scale |
| San Diego Shortness of Breath Score (SD-SOB) Quality of Life Assessment Scores After Treatment With 24 Weeks of Resveratrol and Sirolimus | Treatment Arm | Baseline | 29 | Inter-Quartile Range 21 to 35 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03253913/results